347,433 Shares in Certara, Inc. $CERT Acquired by Y Intercept Hong Kong Ltd

Y Intercept Hong Kong Ltd purchased a new stake in Certara, Inc. (NASDAQ:CERT) during the first quarter, HoldingsChannel reports. The firm purchased 347,433 shares of the company’s stock, valued at approximately $1,980,000.

Several other hedge funds have also added to or reduced their stakes in CERT. Osaic Holdings Inc. increased its holdings in shares of Certara by 50.7% in the second quarter. Osaic Holdings Inc. now owns 3,491 shares of the company’s stock valued at $41,000 after purchasing an additional 1,175 shares during the last quarter. Corient Private Wealth LLC lifted its stake in shares of Certara by 11.7% during the 2nd quarter. Corient Private Wealth LLC now owns 12,362 shares of the company’s stock worth $144,000 after buying an additional 1,295 shares during the last quarter. Treasurer of the State of North Carolina lifted its stake in shares of Certara by 2.9% during the 2nd quarter. Treasurer of the State of North Carolina now owns 56,628 shares of the company’s stock worth $663,000 after buying an additional 1,597 shares during the last quarter. Nicolet Advisory Services LLC boosted its holdings in shares of Certara by 7.4% during the 3rd quarter. Nicolet Advisory Services LLC now owns 30,608 shares of the company’s stock worth $396,000 after buying an additional 2,100 shares during the period. Finally, Amundi boosted its holdings in shares of Certara by 6.7% during the 3rd quarter. Amundi now owns 45,708 shares of the company’s stock worth $615,000 after buying an additional 2,859 shares during the period. Institutional investors and hedge funds own 73.96% of the company’s stock.

Certara Trading Down 8.8%

CERT stock opened at $6.54 on Thursday. The company has a debt-to-equity ratio of 0.28, a quick ratio of 1.88 and a current ratio of 1.88. The company’s 50-day simple moving average is $5.67 and its 200 day simple moving average is $6.80. Certara, Inc. has a 52 week low of $4.45 and a 52 week high of $13.88. The company has a market capitalization of $1.02 billion, a PE ratio of -65.40 and a beta of 1.46.

Certara (NASDAQ:CERT) last released its quarterly earnings results on Monday, May 11th. The company reported $0.09 EPS for the quarter, missing analysts’ consensus estimates of $0.11 by ($0.02). Certara had a positive return on equity of 3.52% and a negative net margin of 3.60%.The business had revenue of $106.92 million for the quarter, compared to the consensus estimate of $106.13 million. During the same period in the prior year, the business posted $0.14 earnings per share. Certara’s revenue was up .8% compared to the same quarter last year. Certara has set its FY 2026 guidance at 0.350-0.410 EPS. As a group, sell-side analysts anticipate that Certara, Inc. will post 0.24 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of research analysts recently commented on the stock. Craig Hallum decreased their price target on shares of Certara from $10.00 to $8.00 and set a “hold” rating on the stock in a research note on Tuesday, May 12th. Barclays reduced their price objective on Certara from $8.00 to $6.50 and set an “equal weight” rating for the company in a report on Tuesday, May 12th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Certara in a research report on Friday, May 29th. Stephens lowered their target price on Certara from $10.00 to $9.00 and set an “overweight” rating on the stock in a research note on Tuesday, May 12th. Finally, KeyCorp dropped their price target on Certara from $10.00 to $8.00 and set an “overweight” rating for the company in a report on Monday, April 13th. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, six have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $8.85.

Certara Company Profile

Certara is a biosimulation software and services company that partners with pharmaceutical, biotechnology and medical device developers to accelerate drug discovery, development and regulatory approval. The company’s platform integrates quantitative pharmacology, real-world evidence, artificial intelligence and machine learning to model and simulate drug behavior across a range of therapeutic areas and patient populations. By applying these mechanistic and data-driven approaches, Certara helps its clients predict clinical outcomes, optimize dosing strategies and streamline decision-making throughout the product lifecycle.

The company’s offerings are divided into software tools and consulting services.